Brii Biosciences Limited
2137.HKHKSEHealthcareBiotechnology
Latest quote
HK$1.01
−HK$0.005 · -0.49%
2137.HK company overview
Regular session · HKT · Market data may be delayed.
Company profile
Company websiteFounded in Beijing, China, in 2017, Brii Biosciences Limited is a biopharmaceutical firm dedicated to discovering and developing innovative therapies for infectious diseases and central nervous system disorders. Its diverse pipeline features: early-stage (Phase 1) compounds BRII-778 and BRII-732 for treating HIV; a multifaceted approach to Hepatitis B (HBV) including a Phase 2 combination study of BRII-179 and BRII-835, with BRII-179 (a recombinant protein-based immunotherapeutic) also in Phase 1b/2a, and BRII-835 having successfully completed Phase 2 for chronic HBV patients. The company also offers the Amubarvimab/romlusevimab combination as a treatment for COVID-19. Beyond these, Brii Biosciences is advancing BRII-296 for PPD and BRII-297 for various depressive conditions, alongside several agents targeting highly resistant infections: BRII-636, BRII-672, and BRII-693 are designed to combat multi-drug and extensively drug-resistant (MDR/XDR) gram-negative bacteria, while BRII-658 is under development for MDR/XDR tuberculosis and non-tuberculosis mycobacterial infections.
- Industry
- Biotechnology
- Sector
- Healthcare
- Headquarters
- CN
- CEO
- Zhi Hong
- Listed since
- Jul 13, 2021
- Employees
- 75
Market position
Day range
Current HK$1.01
52-week range
Current HK$1.01
- Open
- HK$1.00
- Previous close
- HK$1.015
- Volume
- 1.7M
- 1.87× average
- Average volume
- 907.08K
- Average daily volume
- Market cap
- 728.39M HKD
- Beta
- 1.24
- Market reference 1
- 50-day average
- HK$0.9949
- +1.52% above average
- 200-day average
- HK$1.3479
- -25.07% below average
Financials
Financial snapshot
Latest / TTMValuation & yield
- Enterprise value
- 314.52M CNY
- EV / EBITDA
- -1.08×
- Earnings yield
- -23.72%
- Free cash flow yield
- -31.55%
Profitability & efficiency
- Return on equity
- -9.12%
- Return on assets
- -9.19%
- Return on invested capital
- -12.68%
Financial health
- Current ratio
- 60.73×
Earnings
- EPS beat rate
- 27%
- 3 beats, 8 misses, 0 met estimates
- Average EPS surprise
- -2791.60%
- 11 comparable reports
- Latest EPS result
- -0.16
- Estimate -0.11 · Miss by 47.00%
EPS: actual versus estimate
Recent quarterly results
Revenue: actual versus estimate
Recent quarterly results
2137.HK peers
ETFs holding 2137.HK
Funds reporting this stock among their holdings, ordered by reported position size.
State Street SPDR S&P Emerging Markets Small Cap ETFEWX- Market value
- 60.29K
- Weight
- 0.01%
- AUM
- 685.65M USD
- Expense ratio
- 0.65%
- Price / 1D
- $72.22+0.25%
Avantis Emerging Markets Equity ETFAVEM- Market value
- 52.26K
- Weight
- —
- AUM
- 27.89B USD
- Expense ratio
- 0.33%
- Price / 1D
- $94.24+0.75%
Avantis Responsible Emerging Markets Equity ETFAVSE- Market value
- 3.55K
- Weight
- —
- AUM
- 220.3M USD
- Expense ratio
- 0.33%
- Price / 1D
- $78.80+0.82%
Continue in GoAI
Research 2137.HKresearch.disclaimer